International Journal of Healthcare Sciences ISSN 2348-5728 (Online)
Vol. 4, Issue 2, pp: (1099-1104), Month: October 2016 - March 2017, Available at: www.researchpublish.com

Acute ST Elevation Myocardial Infarction Thrombolysed with Streptokinase

[1]Abdullah Osamah Samanudi, [2]Baraa Mohammed Alim, [3]Ahmed Taher Alsulaimani, [4]Ghaida Mohammed Bawazeer, [5]Abdulrahman Mohammed Alshehri, [6]Abdulrahman Ghazi Allahyani

Abstract: **The aim of this study was to discuss the Elevated ST segment in ECG in myocardial infarction (MI), and especially after thrombolysis treatment with streptokinase, also to overview the mechanisms of streptokinase as anticoagulant in MI. A computerized search was conducted through electronic medical databases (PubMed/Midline, Embase, and science-direct) for relevant trails, and articles that were published in English language up to December 17th 2016, and involving human subject. We used following medical heading in our electronic search through mentioned databases; "ST elevation" And "Myocardial infarction" OR "MI", "thrombolysis" "streptokinase". Significant advances in the early detection and reperfusion techniques of acute MI have caused a considerable decrease in morbidity and mortality. To even more optimize the medical outcome in these patients, many efforts have actually been geared towards cardioprotection against myocardial reperfusion injury with mechanical. Cloning of the SK gene in non-pathogenic microorganisms has enabled production of recombinant SK that gets rid of any risk of inadvertent inoculation of patients and production personnel with potentially pathogenic Streptococci. SK can be produced inexpensively in bulk by means of bacterial fermentation espically in MI and therapy of STEMI.**

Keywords: **Streptokinase, myocardial infarction.**

1. INTRODUCTION

When there is occlusion of an epicardial coronary artery, ST elevation is revealed on ECG which is electrical manifestation of the pathophysiological modifications and is known as ST-Elevation Myocardial Infarction (STEMI) [(1)]. Acute myocardial infarction (MI) can be defined by taking into account medical, biochemical, pathological and electrographic attributes. Diagnostic tool for ST segment elevation Myocardial infarction (STEMI) is Electrocardiogram (ECG) and therefore it ought to be done immediately on healthcare facility admission [(2)]. In the United States coronary cardiovascular disease is the leading cause of death with myocardial infarction as one of its presentation. In a research study carried out in 2006, ST elevation was found in one quarter to one third of 1.2 million Americans that had myocardial infarction [(3)]. Despite much better outcomes with early coronary artery reperfusion for the treatment of MI, death from acute myocardial infarction still stays considerable and the occurrence of heart failure is increasing. Unsuccessful thrombolysis resulting in adverse events is usually seen in patients who are not dealt with early [(4,5)]. In the treatment of severe myocardial infarction, early thrombolysis has actually ended up being the recognized fact [(6)]. Thrombus causes closure of vessels in acute myocardial infarction and compromises circulation in unstable angina. Percutaneous intervention is an option for handling severe coronary syndrome and it is associated with higher patency rates of coronary arteries than medical treatment in patients with ST-elevation myocardial infarction (STEMI) [(7)]. In case of ST elevation myocardial infarction, post thrombolytic analysis of ST sector resolution on ECG uses cost effective option to examine coronary reperfusion [(8)].

Successful epicardial vessel thrombolysis is necessary for better prognosis, but the outcome more strongly associates with the micro vascular flow. ST section on ECG is for that reason a much better indicator of prognosis, which cannot be assessed on the basis of cardio angiogram alone [(9,10)]. Streptokinase and Its Use Tillet and Garner [(11)] proved in lab tests in

1933 that streptokinase gotten from the filtrate of Group C beta-hemolytic streptococcus might melt human blood clots. Additional investigations8 showed that streptokinase forms a complex with plasminogen in human blood that activates serum plasmin, the fibrinolytic agent (**Figure 2**). An early objection to the use of streptokinase occurs from its function as an antigen in male. Antibodies to streptokinase are present in all adult people in variable quantities as a result of previous streptococcal infections, and when streptokinase is provided systemically, it responds with the antibodies and is made biochemically inert. This phenomenon makes it challenging to forecast the exact dose of streptokinase required to trigger fibrinolysis in a given patient. The initial amount, or neutralizing dosage, of streptokinase differs from 250,000 to 1,250,000 U [(11,12)]. Patients who are given insufficient loading doses will not have appropriate pharmacological action, while others who take place to get extreme quantities will quickly diminish their distributing plasminogen [(12)].

Objective:

The aim of this study was to discuss the Elevated ST segment in ECG in myocardial infarction (MI), and especially after thrombolysis treatment with streptokinase, also to overview the mechanisms of streptokinase as anticoagulant in MI.

2. METHODOLOGY

A computerized search was conducted through electronic medical databases (PubMed/Midline, Embase, and science-direct) for relevant trails, and articles that were published in English language up to December 17th 2016, and involving human subject. We used following medical heading in our electronic search through mentioned databases; “ST elevation” And “Myocardial infarction” OR “MI”, “thrombolysis” “streptokinase”.
We Furthermore searched the references list of identified studies for more identical articles that could be find supporting our study.

3. RESULTS

- ***Pathophysiology of ST segment elevation Myocardial infarction (STEMI):***

The rupture or erosion of a coronary atherosclerotic plaque is the more regular underlying condition for MI event. In the last 20 years, a strong argument on the structural attributes of a susceptible plaque (a plaque more prone to burst) has actually been performed without a conclusive statement [(13,14)]. In addition, the identification of a susceptible plaque in animal models and human atherogenesis stays questionable. More just recently, the principle of 'vulnerable patients', thinking about various entities (i.e. plaque characteristics, distributing biomarkers, and the action of the injured myocardium), was just recently recommended as a better technique to examine the risk of MI [(15)]. As subclinical procedure characterized by vibrant, non-linear, and unpredictable course, the effort to prospectively determine particular morphological features predictive of plaque rupture, erosion, and medical occasion are likely to be impractical. Rather, existing pathophysiological paradigm considers MI as the result of a 'best storm' circumstance in which a coronary arterial stimulus for scientifically pertinent thrombosis overlaps a pro-thrombotic milieu at the site of plaque rupture or erosion [(15)]. Plaque rupture, which usually happens at the edge or shoulder region, exposes the lipid core, resulting in platelet adhesion and aggregation, activation of the coagulation cascade, and formation of a platelet abundant thrombus. An essential step in this process is activation of prothrombin to thrombin (factor IIa) which promotes the formation of fibrin, the protein which functions as a scaffold in steady thrombus. The fate of the thrombus then varies from easy incorporation into the plaque, through subtotal artery occlusion, to totally occlusive thrombus formation [(16)], the latter typically presenting scientifically as STEMI [(15)].

- ***Reperfusion strategies for STEMI:***

As recently discussed some evidance, the duration of time from sign beginning is a crucial modulator of enhancing option of reperfusion therapy (**Figure 1**) [(17)]. Among patients dealt with within the very first 2 to 3 hours after symptom onset, both clinical trial and computer system registry data highlight that patient results are comparable, irrespective of whether fibrinolytic or mechanical reperfusion is utilized [(18,19)]. The important role of time has actually been re-emphasized by the Mayo Clinic experience showing an almost 3-fold boost in medical facility death after PCI when door-to-balloon times surpassed 2 hours, and likewise after fibrinolysis when door-to-needle times exceeded 1 hour [(20)]. Whereas effectiveness of both kinds of reperfusion therapy is attenuated when delayed, this impact appears especially real for fibrinolytic therapy, resulting in a clear preference for PCI when the time from symptom onset surpasses 3 hours [(21)].



Figure 1: Conceptual model of ST-elevation myocardial infarction nexus modulating choice of reperfusion strategy. The factors comprising the external environmental framework surround the model. Patient, infarct, and risk of reperfusion-specific factors converge with both time from symptom onset and the expected time to achieve PCI in this model.

EMS = emergency medical service; PCI = percutaneous coronary intervention; Rx = treatment; STEMI = ST-elevation myocardial infarction; Sx = symptoms [17]

Where possible, the instant treatment objective in STEMI is to distribute the thrombus consequently bring back coronary blood flow to the culprit artery [21] in order to restrict infarct size, to preserve left ventricular function, and eventually, to lower death. Two decades on from the landmark GISSI trial with streptokinase, fibrinolytic therapy remains the most extensively utilized reperfusion technique [22,23]. Second and 3rd generation fibrinolytic representatives interact directly with clot-bound plasminogen improving fibrin selectivity and achieve higher rates of early patency although this has actually translated at most into only a small further decrease in mortality. More crucial than the fibrinolytic representative used is the time delay from sign onset to drug administration [22,23] and thus the worth of third generation bolus agents which assist in pre-hospital usage. Catheter based reperfusion with main percutaneous coronary intervention (PCI) where offered within a reasonable timeframe, may lead to even much better decrease in cardiovascular events, other than in patients who present extremely rapidly after sign start when both strategies appear to be comparable [24,25]. Main PCI is connected with a minimized risk of bleeding problems, in particular intracranial hemorrhage [24] which normally occurs in around 1% of patients treated with a fibrinolytic based regimen. Trials have actually shown that the adjuvant anticoagulant dose might play a substantial role in the risk of intracranial hemorrhage [26].

- ***Mechanism of Streptokinase Action:***

The particularly fascinating function of this plasminogen activator is that it has no proteolytic activity by itself and thus triggers human plasminogen (HPG) to PN indirectly by very first forming a high affinity equimolar complex with PG (SK - HPG) which is not impacted by a-2-antiplasmin. The capability of SK to form an equimolar complex with HPG has actually been demonstrated [27,28].

There are two important steps in the SK-catalyzed activation of plasminogen [29,30]. The primary step involves development of the proteolytic types which serves as the agent which catalyzes the cleavage of the Arg_{560} - Val_{561} peptide bond necessary for the activation of plasminogen. The occasions which take place in the development of this activator types are summarized listed below [31].

Here, SK and HPG bind in an equimolar complex, yielding SK.HPG. As an outcome of this interaction a conformational change happens in the complex, yielding SK.HPG, having active site. This active site resides in the plasminogen moiety of the complex [30].

In 1941, Milstone [32] reported the presence of a compound, generally present in plasma, that was needed for dissolution of clot. He described it the "lytic factor." Christensen [33,34] and Kaplan [35] individually figured out that the lytic factor was a proteolytic enzyme typically present in plasma as an inactive precursor. The streptococcal substance (fibrinolysin) triggers the proteinase precursor (**Figure 2**) [36], converting it to an active enzyme in a way comparable to the conversion of trypsinogen to trypsin by enterokinase. The active serum proteinase then lyses the fibrin clot. Christensen and MacLeod [37] proposed the term "streptokinase" in 1945 to change the term fibrinolysin initially applied to the streptococcal part of the system. They even more suggested the name "plasminogen" for the non-active form of the serum proteinase and "plasmin" for the active enzyme.



Figure 2: Mechanism of the action of streptokinase. [36]

- ***Pharmacological cardio-protection in ST-segment elevation myocardial by Fibrinolytic therapy (streptokinase):***

The fibrinolytic representatives frequently used in thrombolytic treatment are streptokinase (SK), urokinase (UK) and tissue type plasminogen activator (TPA) [38]. These agents are frequently referred to as plasminogen activators, since their mode of action is through the conversion of the enzymatically inert plasminogen (PG) of the fibrinolytic system to an active protease, plasmin (PN), that liquifies the fibrin embolisms and solubilises deterioration items, which can be eliminated by the phagocytes. This assists to bring back blood circulation through the occluded vessel. Unlike UK and TPA, which themselves proteases, SK possesses no enzymatic activity of its own. Rather, it acquires the extremely specific PG activating residential or commercial property indirectly, by very first forming a high-affinity 1:1 stoichiometric complex with PG or PN. The resultant activator complex is a highly particular protease, which transforms other PG molecules to proteolytically active PN through a series of biochemically distinct steps [31]. The option of a thrombolytic representative throughout therapy is determined by a variety of factors, which depends essentially upon the relative benefits and demerits of specific PG activators. These consist of the expense of the drug, the side-effects and their seriousness, in vivo stability and specificity towards fibrin embolisms and immunological reactivity [38].

4. CONCLUSION

Significant advances in the early detection and reperfusion techniques of acute MI have caused a considerable decrease in morbidity and mortality. To even more optimize the medical outcome in these patients, many efforts have actually been geared towards cardioprotection against myocardial reperfusion injury with mechanical (ischaemic post-conditioning, remote ischaemic pre-conditioning, restorative hypothermia and hypoxemia) and pharmacologic interventions (atrial natriuretic peptide, cyclosporine A, and exenatide). Cloning of the SK gene in non-pathogenic microorganisms has enabled production of recombinant SK that gets rid of any risk of inadvertent inoculation of patients and production personnel with potentially pathogenic Streptococci. SK can be produced inexpensively in bulk by means of bacterial fermentation espically in MI and therapy of STEMI.

REFERENCES

[1] Schröder K, Zeymer U, Wegschneider K, Schroder R. Prediction of outcome in ST elevation myocardial infarction by the extent of ST segment deviation recovery. Which method is best?[in German] Z Kardiol. 2004;93:595–604.

[2] Van de Werf F, Ardissino D, Betriu A. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task force on the management of acute myocardial infarction of the European Society of Cardiology. Eur Heart J. 2003;24:28–66.

[3] American Heart Association. Cardiovascular Disease Statistics. 2006. [Accessed December 17 2016]. at http://www.americanheart.org .

[4] Kloner RA, Rezkalla SH. Cardiac protection during acute myocardial infarction: where do we stand in 2004. J Am Coll Cardiol. 2004;44:276–286.

[5] Topol EJ. Acute myocardial infarction: thrombolysis. A current overview of the benefits and limitations of thrombolytic strategies and the move towards combining thrombolytic agents with glycoprotein IIb/IIIa receptor blockers. Heart. 2000;83:122–126.

[6] Ahmad S, Qureshi MBA, Abbas MZ, Chaudhry MK, Ghani MU. A comparative study of com plications in patients of myocardial infarction managed with and withoutstreptokinase. Pak J Cardio l. 2004;15:61–67.

[7] Afizullah M, Hassan M, Iqbal Z. Primary Coronary Angioplasty in Acute Myocardial Infarction. J Postgrad MedInst. 2001;15:117–125.

[8] van Hof't AW, Liem A, de Boer MJ, Zijlstra F. Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Zwolle Myocardial Infarction Study Group. Lancet. 1997;350:615–619.

[9] Schröder R. Prognostic impact of early ST-segment resolution in acute STelevation myocardial infarction. Circulation. 2004;110:506–510.

[10] deLemos JA, Braunwald E. ST segment resolution as a tool for assessing the efficacy of reperfusion therapy. J Am Coll Cardiol. 2001;38:1283–1294.

[11] Tillet WS, Garner RL. The fibrinolytic activity of hemolytic streptococci. J Exp Med 1933; 58:485.

[12] Barlow GH. Pharmacology of fibrinolytic agents. Prog Cardiovasc Dis 1979; 21:315.

[13] Davies MJ. The pathophysiology of acute coronary syndromes. Heart. 2000;83:361–6.

[14] Shah PK. Mechanisms of plaque vulnerability and rupture. Journal of the American College of Cardiology. 2003;41(4 Suppl S):15S–22S.

[15] Arbab-Zadeh A, Fuster V. The myth of the "vulnerable plaque": transitioning from a focus on individual lesions to atherosclerotic disease burden for coronary artery disease risk assessment. J Am Coll Cardiol 2015;65:846–855.

[16] Corti R, Fuster V, Badimon JJ. Pathogenetic concepts of acute coronary syndromes. Journal of the American College of Cardiology. 2003;41(4 Suppl S):7S–14S.

[17] Armstrong PW, Westerhout CM, Welsh RC. Duration of symptoms is the key modulator of the choice of reperfusion for ST-elevation myocardial infarction. Circulation 2009;119 (9):1293–303.

[18] Steg PG, Bonnefoy E, Chabaud S, Lapostolle F, Dubien PY, Cristofini P, et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial.

Circulation 2003;108(23):2851–6.

[19] Armstrong PW. A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. Eur Heart J 2006;27(13):1530–8.

[20] Ting HH, Rihal CS, Gersh BJ, Haro LH, Bjerke CM, Lennon RJ, et al. Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: the Mayo Clinic STEMI Protocol. Circulation 2007;116(7):729–36.

[21] Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 2004;44(3):E1–211.

[22] Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI) Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1:397–402.

[23] Boersma E, Maas AC, Deckers JW, et al. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet. 1996;348:771–5.

[24] Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13–20.

[25] Steg PG, Bonnefoy E, Chabaud S, et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation. 2003;108:2851–6.

[26] Giugliano RP, McCabe CH, Antman EM, et al. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. American Heart Journal. 2001;141:742–50.

[27] McClintock DK, Bell PH (1971) The mechanism of activation of human plasminogen by streptokinase. Biochem Biophys Res Commun 43:694–702

[28] Summaria L, Arzadon L, Bernabe P, Robbins KC (1974) The interaction of streptokinase with human, cat, dog, and rabbit plasminogens. The fragmentation of streptokinase in the equimolar plasminogen–streptokinase complexes. J Biol Chem 249:4760–4769

[29] Hummel BCW, Schor JM, Buck FF, Boggiano E, DeRenzo EC (1965) Quantitative enzymic assay of human plasminogen and plasmin with azocasein as substrate. Anal Biochem 11:532–547

[30] Reddy KNN, Markus G (1972) Mechanism of activation of human plasminogen by streptokinase presence of active center in streptokinase–plasminogen complex. J Biol Chem 247:1683–1691

[31] Castellino FJ (1981) Recent advances in the chemistry of the fibrinolytic system. Chem Rev 81:431– 446

[32] Milstone H. A factor in normal human blood which participates in streptococcal fibrinolysis. J Immunol 1941;42:109–16.

[33] Christensen LR. The mechanism of streptococcal fibrinolysis [abstract]. J Bact 1944;47:471–2.

[34] Christensen LR. Streptococcal fibrinolysis: a proteolytic reaction due to a serum enzyme activated by streptococcal fibrinolysin. J Gen Physiol 1945;28:363–83.

[35] Kaplan MH. Nature and role of lytic factor in hemolytic streptococcal fibrinolysis. Proc Soc Exp Biol Med 1944;57:40–3.

[36] Sikri N, Bardia A. A History of Streptokinase Use in Acute Myocardial Infarction. *Texas Heart Institute Journal*. 2007;34(3):318-327.

[37] Christensen LR, MacLeod CM. A proteolytic enzyme of se-rum: characterization, activation, and reaction with inhibitors. J Gen Physiol 1945;28:559–83.

[38] Collen D (1990) Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator? Ann Intern Med 112:529–538